Leo Pharma, the Danish dermatology-focused drugmaker, has hired investment banks to manage a potential initial public offering in Copenhagen, according to people familiar with the matter. The listing could come as soon as this year, marking a significant milestone for the Nordic pharmaceutical sector.

The move would give Leo Pharma access to public markets at a time when biotech and pharma listings have shown renewed momentum across Europe. A Copenhagen listing would provide local investors exposure to a company specializing in dermatological treatments, an area where the Danish pharma group has built its reputation over decades.

The timing reflects broader market conditions that have become more favorable for healthcare offerings. Should the IPO proceed, it would represent one of the more notable European pharma listings this year and could encourage other regional drugmakers to consider similar moves.